Novartis reveals positive results from Entresto Phase 4 TRANSITION study for heart failure patients
Swiss pharmaceutical giant Novartis has announced encouraging results from the TRANSITION phase 4 clinical trial, affirming that Entresto (sacubitril/valsartan) can be safely initiated early in ... Read More
Ortho Dermatologics’ Altreno lotion gets FDA approval for Acne treatment
Ortho Dermatologics, a division of Bausch Health Companies, has achieved a significant milestone with the FDA approval of Altreno lotion (tretinoin 0.05%) for the treatment ... Read More
Alnylam Pharmaceuticals completes patient enrollment for Phase 3 trial of givosiran in acute hepatic porphyrias
Alnylam Pharmaceuticals has announced the completion of patient enrollment for its pivotal phase 3 trial, ENVISION, which evaluates the efficacy of givosiran in treating acute ... Read More
Array BioPharma’s new colorectal cancer treatment gains breakthrough therapy designation from FDA
Array BioPharma has achieved a significant regulatory milestone as its innovative combination therapy for metastatic colorectal cancer (mCRC) has been granted breakthrough therapy designation by ... Read More
Protagonist Therapeutics secures $22m to advance IBD treatment
Protagonist Therapeutics, a clinical-stage biopharmaceutical company specializing in the discovery and development of novel peptide-based drugs, has successfully raised $22 million in new equity financing. ... Read More
Britannia Pharmaceuticals’ apomorphine shows promise in Phase 3 TOLEDO trial for Parkinson’s disease
Britannia Pharmaceuticals, a subsidiary of the British pharma group, has announced successful Phase 3 results for its APO-go/MOVAPO (apomorphine) subcutaneous infusion, marking a significant advancement ... Read More
Vyriad and Merck launch Phase 1 trial for innovative immuno-oncology drug combination
Vyriad, a US-based biotech company, has partnered with Germany's Merck to initiate a Phase 1 clinical trial targeting metastatic colorectal cancer. This trial explores the ... Read More
Prevacus partners with Blinktbi for advanced concussion drug trials
Prevacus, a leading US biopharmaceutical company, has announced a strategic partnership with medical device company Blinktbi, utilizing their novel EyeStat device to measure brain function ... Read More
Breakthrough Alzheimer’s treatments on the horizon: New drugs and potential vaccine
Global Health Update — Promising developments in the fight against Alzheimer's disease could significantly alter the landscape of treatment and prevention within the next decade. ... Read More
Eli Lilly’s Cyramza fails to improve survival in gastric cancer trial despite meeting initial goal
In a recent announcement, Eli Lilly and Company disclosed that its phase 3 RAINFALL trial of the drug Cyramza (ramucirumab) for the treatment of HER2-negative ... Read More